Day One Biopharmaceuticals Q3 revenue beats estimates on OJEMDA strength

Day One Biopharmaceuticals

04/11/2025 21:09

Overview

Day One Q3 revenue of $39.8 mln beats analyst expectations

OJEMDA net product revenue rises 15% from Q2, driven by higher patient demand

Company raises full-year 2025 OJEMDA revenue guidance to $145-$150 mln

Outlook

Company raises OJEMDA full-year 2025 revenue guidance to $145-$150 mln

Result Drivers

INCREASED DEMAND - OJEMDA net product revenue rose 15% from Q2 2025, driven by higher patient demand

CLINICAL DATA IMPACT - New patient starts grew 19% in Q3 2025, driven by FIREFLY-1 clinical trial data

REVENUE GUIDANCE RAISED - Co raises full-year 2025 OJEMDA revenue guidance to $145-$150 mln, reflecting strong demand

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$39.80 mln
$38.20 mln (9 Analysts)
Q3 EPS
-$0.19
Q3 Net Income
-$19.72 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Day One Biopharmaceuticals Inc is $25.00, about 70.8% above its November 3 closing price of $7.31

Press Release: ID:nGNX4Mx6H3

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)